The stock of Merus N.V.HARES (NASDAQ:MRUS) registered an increase of 3.96% in short interest. MRUS’s total short interest was 372,400 shares in March as published by FINRA. Its up 3.96% from 358,200 shares, reported previously. With 18,800 shares average volume, it will take short sellers 20 days to cover their MRUS’s short positions. The short interest to Merus N.V.HARES’s float is 5.68%.
The stock decreased 1.37% or $0.18 during the last trading session, reaching $12.95. About 3,309 shares traded. Merus N.V. (NASDAQ:MRUS) has declined 28.39% since March 17, 2018 and is downtrending. It has underperformed by 32.76% the S&P500.
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. The company has market cap of $294.41 million. The Company’s lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers. It currently has negative earnings. The firm also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies, as well as developing MCLA-158, a bispecific antibody candidate, which is designed to bind to cancer stem cells for the potential treatment of colorectal cancer.
More notable recent Merus N.V. (NASDAQ:MRUS) news were published by: Benzinga.com which released: “Most Notable Abstracts Released Ahead Of ASCO 2017 – Benzinga” on May 19, 2017, also Benzinga.com with their article: “The Daily Biotech Pulse: Opko Settles With SEC, Obalon Inks Financing Deals, Harpoon Files For IPO – Benzinga” published on December 28, 2018, Globenewswire.com published: “Merus Announces Pricing of Initial Public Offering – GlobeNewswire” on May 18, 2016. More interesting news about Merus N.V. (NASDAQ:MRUS) were released by: Seekingalpha.com and their article: “Many Risks For The Merus B.V. IPO – Seeking Alpha” published on May 16, 2016 as well as Nasdaq.com‘s news article titled: “Amarin Down on Lower ’19 View, Posts Preliminary ’18 Results – Nasdaq” with publication date: January 07, 2019.